RecruitingNot Applicable

The Effeciency of NMN in Improving IVF/ICSI-ET Pregnancy Outcomes in Patients With DOR

China200 participantsStarted 2023-10-01

Plain-language summary

The purpose of the study is to understand the effect of nicotinamide mononucleotide (NMN) on patients with diminished ovarian reserve and the outcomes of IVF/ICSI-ET.

Who can participate

Age range20 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Individuals who are 20 to 40 years old.
✓. At least two of the following three conditions should be met:
✓. The concentrations of anti-Mullerian hormone \< 1.1 ng/ml,
✓. the values of antral follicle count was less than 7
✓. serum concentrations of day-3 follicle-stimulating hormone (FSH)： 10 IU/L ≤ FSH\<20 IU/L
✓. Individuals who can insist on continuous monitoring in the outpatient clinic.
✓. Individuals who are not participating in other research projects currently or 3 months before the intervention.

Exclusion criteria

✕. Individuals who are during pregnant, lactation or menopause.
✕. Individuals who had non-46-XX karyotype, or attributed to known genetic etiology.
✕. Cancer patients or receiving chemo/radiotherapy treatment within the past 5 years.
✕. Individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc.
✕. Individuals who currently receiving weight-loss drugs or surgery or within the past 2 months.
✕. Use of medications or traditional Chinese medicine that affect hormone levels, appetite, carbohydrate absorption, and metabolism within the past 3 months.
✕. Individuals who take niacin, nicotinamide, or other vitamin B3-related supplementation, or other supplementation such as coenzyme Q10, vitamin E currently or within the past 3 months.
✕. Use of antibiotics, probiotics, or prebiotics that affect the flora within the past 3 months.

What they're measuring

The clinical pregnancy rate

Timeframe: through study completion, an average of 2 year

Trial details

NCT IDNCT06426355

SponsorPeking University Third Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02

Contact for this trial

Mengyu Liu, PhD

15611555481 myl1995lmy@163.com

View on ClinicalTrials.gov More Diminished Ovarian Reserve trials